These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25875403)

  • 1. Tricyclic dihydrobenzoxazepine and tetracyclic indole derivatives can specifically target bacterial DNA ligases and can distinguish them from human DNA ligase I.
    Yadav N; Khanam T; Shukla A; Rai N; Hajela K; Ramachandran R
    Org Biomol Chem; 2015 May; 13(19):5475-87. PubMed ID: 25875403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I.
    Srivastava SK; Dube D; Tewari N; Dwivedi N; Tripathi RP; Ramachandran R
    Nucleic Acids Res; 2005; 33(22):7090-101. PubMed ID: 16361267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: novel structure-function relationship and identification of a specific inhibitor.
    Srivastava SK; Dube D; Kukshal V; Jha AK; Hajela K; Ramachandran R
    Proteins; 2007 Oct; 69(1):97-111. PubMed ID: 17557328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure based identification of first-in-class fragment inhibitors that target the NMN pocket of M. tuberculosis NAD
    Shukla A; Afsar M; Kumar N; Kumar S; Ramachandran R
    J Struct Biol; 2021 Mar; 213(1):107655. PubMed ID: 33197566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of NAD(+) -dependent DNA ligase of mycobacteria as a potential target for antibiotics.
    Korycka-Machala M; Rychta E; Brzostek A; Sayer HR; Rumijowska-Galewicz A; Bowater RP; Dziadek J
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2888-97. PubMed ID: 17548501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Novel Inhibitors of
    Alomari A; Gowland R; Southwood C; Barrow J; Bentley Z; Calvin-Nelson J; Kaminski A; LeFevre M; Callaghan AJ; Vincent HA; Gowers DM
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33923034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homology modeling of NAD+-dependent DNA ligase of the Wolbachia endosymbiont of Brugia malayi and its drug target potential using dispiro-cycloalkanones.
    Shrivastava N; Nag JK; Pandey J; Tripathi RP; Shah P; Siddiqi MI; Misra-Bhattacharya S
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3736-47. PubMed ID: 25845868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo.
    Mills SD; Eakin AE; Buurman ET; Newman JV; Gao N; Huynh H; Johnson KD; Lahiri S; Shapiro AB; Walkup GK; Yang W; Stokes SS
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1088-96. PubMed ID: 21189350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward the virtual screening of potential drugs in the homology modeled NAD+ dependent DNA ligase from Mycobacterium tuberculosis.
    Singh V; Somvanshi P
    Protein Pept Lett; 2010 Feb; 17(2):269-76. PubMed ID: 20214650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAD+-dependent DNA Ligase (Rv3014c) from Mycobacterium tuberculosis. Crystal structure of the adenylation domain and identification of novel inhibitors.
    Srivastava SK; Tripathi RP; Ramachandran R
    J Biol Chem; 2005 Aug; 280(34):30273-81. PubMed ID: 15901723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part 2: 4-amino-pyrido[2,3-d]pyrimidin-5(8H)-ones.
    Wang T; Duncan L; Gu W; O'Dowd H; Wei Y; Perola E; Parsons J; Gross CH; Moody CS; Arends SJ; Charifson PS
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3699-703. PubMed ID: 22560470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAD+-dependent DNA ligases of Mycobacterium tuberculosis and Streptomyces coelicolor.
    Wilkinson A; Sayer H; Bullard D; Smith A; Day J; Kieser T; Bowater R
    Proteins; 2003 May; 51(3):321-6. PubMed ID: 12696044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Base-modified NAD and AMP derivatives and their activity against bacterial DNA ligases.
    Pergolizzi G; Cominetti MM; Butt JN; Field RA; Bowater RP; Wagner GK
    Org Biomol Chem; 2015 Jun; 13(22):6380-98. PubMed ID: 25974621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones.
    Brötz-Oesterhelt H; Knezevic I; Bartel S; Lampe T; Warnecke-Eberz U; Ziegelbauer K; Häbich D; Labischinski H
    J Biol Chem; 2003 Oct; 278(41):39435-42. PubMed ID: 12867414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of an inhibitor specific to bacterial NAD+-dependent DNA ligases.
    Meier TI; Yan D; Peery RB; McAllister KA; Zook C; Peng SB; Zhao G
    FEBS J; 2008 Nov; 275(21):5258-71. PubMed ID: 18795946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M. tuberculosis class II apurinic/ apyrimidinic-endonuclease/3'-5' exonuclease (XthA) engages with NAD+-dependent DNA ligase A (LigA) to counter futile cleavage and ligation cycles in base excision repair.
    Khanam T; Afsar M; Shukla A; Alam F; Kumar S; Soyar H; Dolma K; Pasupuleti M; Srivastava KK; Ampapathi RS; Ramachandran R
    Nucleic Acids Res; 2020 May; 48(8):4325-4343. PubMed ID: 32232338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification through structure-based methods of a bacterial NAD(+)-dependent DNA ligase inhibitor that avoids known resistance mutations.
    Murphy-Benenato K; Wang H; McGuire HM; Davis HE; Gao N; Prince DB; Jahic H; Stokes SS; Boriack-Sjodin PA
    Bioorg Med Chem Lett; 2014 Jan; 24(1):360-6. PubMed ID: 24287382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part I: aminoalkoxypyrimidine carboxamides.
    Gu W; Wang T; Maltais F; Ledford B; Kennedy J; Wei Y; Gross CH; Parsons J; Duncan L; Arends SJ; Moody C; Perola E; Green J; Charifson PS
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3693-8. PubMed ID: 22560473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of the eubacterial DNA ligase by arylamino compounds.
    Ciarrocchi G; MacPhee DG; Deady LW; Tilley L
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2766-72. PubMed ID: 10543760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Optimization of NAD+-Dependent DNA Ligase Inhibitors as Novel Antibacterial Compounds.
    Bi F; Ma R; Ma S
    Curr Pharm Des; 2017; 23(14):2117-2130. PubMed ID: 27784238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.